Actively Recruiting
Phase II Study of TriAdeno Vaccine and IL-15 Superagonist N-803 in Men with Localized Prostate Cancer Under Active Surveillance
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
52
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Prostate cancer is a common and serious cancer among men, often managed with active surveillance when detected early. However, many men experience tumor growth requiring treatment within five years. This trial evaluates a new vaccine called TriAdeno, which targets three cancer-related proteins, combined with the drug N-803, to see if this approach can help stop tumor growth in men with early-stage, low- to intermediate-risk prostate cancer. Participants receive the TriAdeno vaccine and N-803 injections under the skin on the first day of each 21-day cycle, for up to four cycles. The vaccine targets prostate cancer antigens PSA, brachyury, and MUC-1, while N-803 is an immune system stimulant. A biopsy will be taken during or after the second cycle and possibly again after about one year. Participants may also track their symptoms and complete questionnaires about prostate health during the study. Throughout the trial, participants undergo physical exams, blood tests, heart function assessments, and imaging scans. Tumor biopsies will be analyzed for immune cell infiltration. Follow-up phone calls will continue for five years to monitor safety and cancer status. The study aims to measure immune response changes in the tumor and track prostate-specific antigen PSA levels over time.
CONDITIONS
Brief Title
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Research Team
G
Genevieve C Fromm
P
Peter A Pinto, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here